A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required